Moleculin Biotech, Inc. (NASDAQ:MBRX) went up by 5.32% from its latest closing price compared to the recent 1-year high of $1.97. The company’s stock price has collected 4.18% of gains in the last five trading sessions. Press Release reported 0 hour ago that Moleculin Announces COVID-19 In Vivo Testing Contracted for WP1122
Is It Worth Investing in Moleculin Biotech, Inc. (NASDAQ :MBRX) Right Now?
Moleculin Biotech, Inc. (NASDAQ:MBRX) scored a price-to-earnings ratio above its average ratio, recording 17.24 x from its present earnings ratio. Plus, the 36-month beta value for MBRX is at 2.19. Opinions of the stock are interesting as 3 analysts out of 3 who provided ratings for Moleculin Biotech, Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $3.33, which is -$0.8 below the current price. MBRX currently public float of 54.73M and currently shorts hold a 6.20% ratio of that float. Today, the average trading volume of MBRX was 3.21M shares.
MBRX’s Market Performance
MBRX stocks went up by 4.18% for the week, with a monthly drop of -19.22% and a quarterly performance of -28.57%, while its annual performance rate touched -30.43%. The volatility ratio for the week stands at 8.45% while the volatility levels for the past 30 days are set at 6.25% for Moleculin Biotech, Inc.. The simple moving average for the period of the last 20 days is -8.02% for MBRX stocks with a simple moving average of -14.67% for the last 200 days.
MBRX Trading at -18.33% from the 50-Day Moving Average
After a stumble in the market that brought MBRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.39% of loss for the given period.
Volatility was left at 6.25%, however, over the last 30 days, the volatility rate increased by 8.45%, as shares sank -18.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.80% lower at present.
During the last 5 trading sessions, MBRX rose by +4.18%, which changed the moving average for the period of 200-days by -26.61% in comparison to the 20-day moving average, which settled at $0.8605. In addition, Moleculin Biotech, Inc. saw -12.58% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for MBRX
The total capital return value is set at -115.97, while invested capital returns managed to touch -87.69. Equity return is now at value -117.70, with -68.50 for asset returns.
Based on Moleculin Biotech, Inc. (MBRX), the company’s capital structure generated 2.43 points at debt to equity in total, while total debt to capital is 2.38.